A survey of products licensed in the United Kingdom from 1971-1981.
作者信息
Griffin J P, Diggle G E
出版信息
Br J Clin Pharmacol. 1981 Oct;12(4):453-63. doi: 10.1111/j.1365-2125.1981.tb01251.x.
Abstract
摘要
相似文献
1
A survey of products licensed in the United Kingdom from 1971-1981.一项对1971年至1981年在英国获得许可的产品的调查。
Br J Clin Pharmacol. 1981 Oct;12(4):453-63. doi: 10.1111/j.1365-2125.1981.tb01251.x.
2
Post-marketing surveillance of licensed medicinal and other products.
Health Bull (Edinb). 1981 Nov;39(6):356-66.
3
Requirements to be fulfilled before instituting clinical trials on new drugs.
Proc R Soc Med. 1974 Jun;67(7):581-4. doi: 10.1177/003591577406700701.
4
II. Control of medicinal products in the United Kingdom.
Bull Parenter Drug Assoc. 1974 Jul-Aug;28(4):161-6.
5
Legislation and drug safety.立法与药物安全。
J Clin Pathol Suppl (R Coll Pathol). 1975;9:119-21.
6
Regulatory concerns at various phases of drug development.药物研发各个阶段的监管问题。
Am J Cardiol. 1998 Apr 23;81(8A):2F-4F. doi: 10.1016/s0002-9149(98)00250-1.
7
[New order in drug legislation].
Dtsch Med Wochenschr. 1975 Apr 25;100(17):972-6.
8
IV. Recent medicine legislation in the United Kingdom and its effect on manufacturing practice.
Bull Parenter Drug Assoc. 1974 Jul-Aug;28(4):174-80.
9
Psychotropic drug registration in the Scandinavian countries: the role of clinical trials.
Soc Sci Med Med Psychol Med Sociol. 1980 Dec;14A(6):547-59. doi: 10.1016/0160-7979(80)90057-0.
10
Regulations and procedures for new drug evaluation and approval in China.中国新药审评审批的法规和程序。
Hum Gene Ther. 2006 Oct;17(10):970-4. doi: 10.1089/hum.2006.17.970.
引用本文的文献
1
The need for pharmacoeconomic evaluations in the NHS.英国国家医疗服务体系（NHS）中药物经济学评估的必要性。
Pharmacoeconomics. 1998 Sep;14(3):241-50. doi: 10.2165/00019053-199814030-00001.
2
Therapeutic conservatism: more costly in the long term? A UK perspective.治疗保守主义：从长远来看成本更高？英国视角。
Pharmacoeconomics. 1995 May;7(5):378-87. doi: 10.2165/00019053-199507050-00002.
3
U.K. drug control: retrospect and prospect.英国的药物管制：回顾与展望
Br J Clin Pharmacol. 1981 Oct;12(4):449-51. doi: 10.1111/j.1365-2125.1981.tb01250.x.
4
Ten years of The Medicines Act.
Br J Clin Pharmacol. 1981 Oct;12(4):447-8. doi: 10.1111/j.1365-2125.1981.tb01249.x.
5
The role of the pharmaceutical industry in diabetes research.
Diabetologia. 1982 Sep;23(3):216-9. doi: 10.1007/BF00252844.
6
Six months experience of new procedures affecting the conduct of clinical trials in the United Kingdom.影响英国临床试验开展的新程序的六个月经验。
Br J Clin Pharmacol. 1982 Feb;13(2):253-5. doi: 10.1111/j.1365-2125.1982.tb01374.x.
7
A survey of the first year of operation of the new procedure affecting the conduct of clinical trials in the United Kingdom.对影响英国临床试验开展的新程序运行第一年的调查。
Br J Clin Pharmacol. 1983 Jun;15(6):649-55. doi: 10.1111/j.1365-2125.1983.tb01545.x.
8
Crying wolf on drug safety.在药物安全问题上谎报险情。
Br Med J (Clin Res Ed). 1982 Jan 23;284(6311):219-20.
9
How many medicines are there?有多少种药物？
Br Med J (Clin Res Ed). 1985 Mar 9;290(6470):773-4. doi: 10.1136/bmj.290.6470.773.
10
Trends in the development of new medicines by UK-owned pharmaceutical companies (1964-1980).英国制药公司新药研发趋势（1964 - 1980年）
Br J Clin Pharmacol. 1986 Apr;21(4):437-43. doi: 10.1111/j.1365-2125.1986.tb05219.x.
本文引用的文献
1
Drug innovation--what's slowing it down?药物创新——是什么在减缓其发展？
Nature. 1980 Mar 13;284(5752):118-20. doi: 10.1038/284118a0.
2
Constraints of drug regulation on the development of new drugs.
Arch Toxicol. 1979 Oct;43(1):9-17. doi: 10.1007/BF00695869.
Zotero 插件